Publications

After receiving recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel (LN-44) in the treatment of advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application (BLA) submission during the first quarter of 2023.

The FDA granted orphan drug designation to AVS100 for the treatment of stage IIB through stage IV melanoma, according to the agent’s manufacturer.

Changes to the Medicare Benefits Schedule (MBS) will have some impact on general practice as of 1 November, including for melanoma excision services and cycle-of-care items for chronic disease management. newsGP summarises the key changes.